Literature DB >> 34923885

1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies.

Mohamed Hagras1, Marwa A Saleh2, Rogy R Ezz Eldin3, Abdelrahman A Abuelkhir1, Emad Gamil Khidr4, Ahmed A El-Husseiny4, Hesham A El-Mahdy4, Eslam B Elkaeed5, Ibrahim H Eissa6.   

Abstract

In the current work, some 1,3,4-oxadiazole-naphthalene hybrids were designed and synthesised as VEGFR-2 inhibitors. The synthesised compounds were evaluated in vitro for their antiproliferative activity against two human cancer cell lines namely, HepG-2 and MCF-7. Compounds that exhibited promising cytotoxicity (5, 8, 15, 16, 17, and 18) were further evaluated for their VEGFR-2 inhibitory activities. Compound 5 showed good antiproliferative activity against both cell lines and inhibitory effect on VEGFR-2. Besides, it induced apoptosis by 22.86% compared to 0.51% in the control (HepG2) cells. This apoptotic effect was supported by a 5.61-fold increase in the level of caspase-3 compared to the control cells. Moreover, it arrested the HepG2 cell growth mostly at the Pre-G1 phase. Several in silico studies were performed including docking, ADMET, and toxicity studies to predict binding mode against VEGFR-2 and to anticipate pharmacokinetic, drug-likeness, and toxicity of the synthesised compounds.

Entities:  

Keywords:  1,3,4-oxadiazole; Anticancer; VEGFR-2 inhibitors; apoptosis; docking

Mesh:

Substances:

Year:  2022        PMID: 34923885      PMCID: PMC8725909          DOI: 10.1080/14756366.2021.2015342

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  72 in total

Review 1.  The Draize eye test.

Authors:  K R Wilhelmus
Journal:  Surv Ophthalmol       Date:  2001 May-Jun       Impact factor: 6.048

2.  Novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene)thiazolidin-2-ylidene)amino) benzenesulfonamides: Synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies.

Authors:  Wagdy M Eldehna; Mahmoud F Abo-Ashour; Alessio Nocentini; Paola Gratteri; Ibrahim H Eissa; Mohamed Fares; Omnia E Ismael; Hazem A Ghabbour; Mahmoud M Elaasser; Hatem A Abdel-Aziz; Claudiu T Supuran
Journal:  Eur J Med Chem       Date:  2017-08-01       Impact factor: 6.514

3.  Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers.

Authors:  Hazem A Mahdy; Mohammed K Ibrahim; Ahmed M Metwaly; Amany Belal; Ahmed B M Mehany; Kamal M A El-Gamal; Abdou El-Sharkawy; Mostafa A Elhendawy; Mohamed M Radwan; Mahmoud A Elsohly; Ibrahim H Eissa
Journal:  Bioorg Chem       Date:  2019-11-12       Impact factor: 5.275

4.  Rational design of inhibitors that bind to inactive kinase conformations.

Authors:  Yi Liu; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2006-07       Impact factor: 15.040

Review 5.  Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Gynecol Oncol       Date:  2013-12-03       Impact factor: 5.482

6.  Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay.

Authors:  M I Thabrew; R D Hughes; I G McFarlane
Journal:  J Pharm Pharmacol       Date:  1997-11       Impact factor: 3.765

7.  Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase.

Authors:  Ahmed Ismail; Ahmed S Doghish; Bakheet E M Elsadek; Salama A Salama; Amr D Mariee
Journal:  Steroids       Date:  2020-05-18       Impact factor: 2.668

8.  Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme.

Authors:  Khaled El-Adl; Abdel-Ghany A El-Helby; Helmy Sakr; Ibrahim H Eissa; Sanadelaslam S A El-Hddad; Fatma M I A Shoman
Journal:  Bioorg Chem       Date:  2020-06-30       Impact factor: 5.275

9.  Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.

Authors:  Yan Song; Jinwan Wang; Xiubao Ren; Jie Jin; Li Mao; Chris Liang; Lieming Ding; Lin Yang
Journal:  Chin J Cancer Res       Date:  2021-02-28       Impact factor: 5.087

10.  Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers.

Authors:  Asmaa E Kassab; Ehab M Gedawy; Mohammed I A Hamed; Ahmed S Doghish; Rasha A Hassan
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

View more
  1 in total

1.  Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer.

Authors:  Esraa A Abdelsalam; Amer Ali Abd El-Hafeez; Wagdy M Eldehna; Mahmoud A El Hassab; Hala Mohamed M Marzouk; Mahmoud M Elaasser; Nageh A Abou Taleb; Kamilia M Amin; Hatem A Abdel-Aziz; Pradipta Ghosh; Sherif F Hammad
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.